PsychRounds: The Psychiatry Podcast

Welcome back! Today we are featuring the two FDA-approved medications for tardive dyskinesia, the VMAT2 inhibitors Valbenazine (Ingrezza) and Deutetrabenazine (Austedo).

References:
https://pubmed.ncbi.nlm.nih.gov/41626799/
https://www.ncbi.nlm.nih.gov/books/NBK548187/
https://pubmed.ncbi.nlm.nih.gov/41626799/

We are back with another special guest episode! Please welcome Dr. Allen Frances, who was intricately involved in the formation of both the DSM III and DSM IV, the latter of which he served as chair.

https://x.com/AllenFrancesMD
https://www.amazon.com/stores/author/B001HO76FU
https://www.psychiatrictimes.com/authors/allen-frances-md

Welcome back! Today we will be doing a brief episode on Topiramate [Topamax], and its clinical uses in psychiatry.

References:
https://pubmed.ncbi.nlm.nih.gov/21438989/

https://pubmed.ncbi.nlm.nih.gov/18774432/

https://pubmed.ncbi.nlm.nih.gov/25899459/

https://pmc.ncbi.nlm.nih.gov/articles/PMC1088011/

https://pmc.ncbi.nlm.nih.gov/articles/PMC2671954/

https://pubmed.ncbi.nlm.nih.gov/38706338/

https://pubmed.ncbi.nlm.nih.gov/20207521/

Welcome back, today we are discussing a deceptively difficult topic: What makes something a psychiatric illness? We are joined by our guest Dr. Mark Ruffalo. He is a psychotherapist in private practice in Tampa, FL, and who also serves as Assistant Professor of Psychiatry at the University of Central Florida College of Medicine as well an Adjunct Assistant Professor of Psychiatry at Tufts University School of Medicine. 
Dr. Ruffalo's Website: https://www.drruffalo.com/
Dr. Ruffalo's LinkedIn: https://www.linkedin.com/in/mark-l-ruffalo-71929063
PRISM: https://www.psychiatrictimes.com/view/use-of-the-prism-diagnostic-instrument-in-clinical-practice
PRISM Writing Contest: https://www.psychiatrictimes.com/view/prism-writing-contest-more-on-this-new-diagnostic-tool-from-mark-ruffalo-msw-dpsa

Welcome back! Today we are at the highly prescribed and popular benzodiazepine Lorazepam, also known as Ativan. We look at its uses in psychiatry, especially catatonia. But despite anecdotal efficacy, does the evidence hold up?

References:
https://www.ncbi.nlm.nih.gov/books/NBK532890/

https://pubmed.ncbi.nlm.nih.gov/36805317/

https://pubmed.ncbi.nlm.nih.gov/6120058/

https://pubmed.ncbi.nlm.nih.gov/10229064/

https://psychopharmacologyinstitute.com/section/catatonia-diagnosis-the-lorazepam-challenge-2911-5899/